Chemical Characteristics of Platycodon grandiflorum and its Mechanism in Lung Cancer Treatment.
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer.
Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, Kaneda H, Hasegawa Y, Tanaka K, Takeda M, Nakagawa K.
JAMA Oncol. 2018 Mar 1;4(3):374-378. doi: 10.1001/jamaoncol.2017.2925.
Cancer prevention with rapamycin.
Blagosklonny MV.
Oncotarget. 2023 Apr 14;14:342-350. doi: 10.18632/oncotarget.28410.
Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures.
Wei F, Azuma K, Nakahara Y, Saito H, Matsuo N, Tagami T, Kouro T, Igarashi Y, Tokito T, Kato T, Kondo T, Murakami S, Usui R, Himuro H, Horaguchi S, Tsuji K, Murotani K, Ban T, Tamura T, Miyagi Y, Sasada T.
J Immunother Cancer. 2023 Jul;11(7):e006788. doi: 10.1136/jitc-2023-006788.
Treatment of Small Cell Lung Cancer with Lurbinectedin: A Review.
Rajput PS, Khan SR, Singh P, Chawla PA.
Anticancer Agents Med Chem. 2022;22(5):812-820. doi: 10.2174/1871520621666210706150057.
Overcoming lung cancer immunotherapy resistance by combining nontoxic variants of IL-12 and IL-2.
Horton BL, D'Souza AD, Zagorulya M, McCreery CV, Abhiraman GC, Picton L, Sheen A, Agarwal Y, Momin N, Wittrup KD, White FM, Garcia KC, Spranger S.
JCI Insight. 2023 Oct 9;8(19):e172728. doi: 10.1172/jci.insight.172728.
Impact of Lung Cancer Treatment on Cognitive Functioning.
van de Kamp HJ, Molder MT, Schulkes KJG, Stellingwerf M, van Elden LJR, van Lindert ASR, Hamaker ME.
Clin Lung Cancer. 2020 Mar;21(2):114-126.e3. doi: 10.1016/j.cllc.2019.06.006. Epub 2019 Jun 15.
PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer.
Barlesi F, Cho BC, Goldberg SB, Yoh K, Zimmer Gelatti AC, Mann H, Gopinathan A, Bielecka ZF, Newton M, Aggarwal C.
Future Oncol. 2024;20(29):2137-2147. doi: 10.1080/14796694.2024.2354160. Epub 2024 Jul 18.
Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities.
Suresh K, Naidoo J, Lin CT, Danoff S.
Chest. 2018 Dec;154(6):1416-1423. doi: 10.1016/j.chest.2018.08.1048. Epub 2018 Sep 4.
Nano-mediated strategy for targeting and treatment of non-small cell lung cancer (NSCLC).
Ashique S, Garg A, Mishra N, Raina N, Ming LC, Tulli HS, Behl T, Rani R, Gupta M.
Naunyn Schmiedebergs Arch Pharmacol. 2023 Nov;396(11):2769-2792. doi: 10.1007/s00210-023-02522-5. Epub 2023 May 23.
The potential applications of microparticles in the diagnosis, treatment, and prognosis of lung cancer.
Liu Y, Wang S, Xia H, Tan X, Song S, Zhang S, Meng D, Chen Q, Jin Y.
J Transl Med. 2022 Sep 5;20(1):404. doi: 10.1186/s12967-022-03599-x.
